查看文章

To evaluate the effects of loteprednol etabonate (LE) 0.2% in reducing the signs and symptoms of seasonal allergic conjunctivitis.

Randomized, double-masked, placebo-controlled, parallel group multicenter study of 6 weeks duration.

A total of 135 patients with signs and symptoms of seasonal allergic conjunctivitis participated.

All patients received either LE 0.2% or placebo (vehicle) four times a day in both eyes for 42 days.

Bulbar conjunctival injection (primary sign) and itching (primary symptom) over the first 2 weeks of treatment was measured.

A reduction in severity was seen in both LE and placebo groups for bulbar conjunctival injection (1.5 vs. 1.0 units on a 0–3 scale) and itching (3.4 vs. 3.0 units on a 0–4 scale) over the first 2 weeks. The treatment effect by these measures was −0.5 and −0.4 units in favor of LE …